Barrx Medical Inc.
SUNNYVALE, California, November 21, 2011 -
BARRX Medical Inc., a leader in developing minimally invasive medical devices used in conjunction with endoscopy to remove precancerous tissue from the gastrointestinal tract, announces today that they have signed a definitive agreement to be acquired by Covidien. Covidien is a leading global provider of healthcare products and a worldwide leader in advanced energy-based devices.
Covidien will acquire all of the outstanding capital stock of BARRX, a private company, for approximately $325 million, with additional future earn out payments possible upon achievement of company milestones. The transaction, subject to customary closing conditions, is expected to be completed by January 31, 2012.
SUNNYVALE, California, March 10, 2011 - BARRX Medical, Inc., a leader in developing minimally invasive medical
devices to remove precancerous tissue from the gastrointestinal tract,
reported today that the American Gastroenterological Association (AGA) has
issued the AGA Medical Position Statement on the Treatment of Barrett's
Esophagus.
SUNNYVALE, California, July 14, 2010 - BARRX Medical, Inc.
SUNNYVALE, California, June 28, 2010 - BARRX Medical Inc., a world leader in products to treat pre-cancerous
tissue in the esophagus, reported today that the National Institute for
Health and Clinical Excellence (NICE) in the United Kingdom has published new
guidelines approving the use of radiofrequency ablation for the eradication
of dysplastic Barrett's esophagus.
SUNNYVALE, California, June 1, 2010 - BARRX Medical Inc., a leader in the development of minimally invasive
medical devices designed to remove precancerous tissue from within the
gastrointestinal tract, reported today that the Society of American
Gastrointestinal and Endoscopic Surgeons (SAGES) has issued a new practice
guideline for the surgical treatment of gastroesophageal reflux disease
(GERD).